The Antimicrobial Stewardship Project (ASP)

CIDRAP-ASP was launched in July 2016 with the aim to build an international audience and a portfolio of research that translates scientific information to evidence-informed public health practice and policy.

Our Goal

Equip global health professionals, patients and the public with the most relevant and important key findings, knowledge and policy recommendations relating to antimicrobial resistance.

Our program is built on three pillars:

  • Communication and Advocacy: providing timely access to latest news related to antimicrobial stewardship and research on our dedicated website and social media.

  • Education and Awareness: raising awareness on AMR and how to promote responsible use of antimicrobials through mentoring and dedicated activities such as webinars and podcasts.

  • Research: conducting analysis to advance the knowledge on a specific topic.

Reports & Activities

  • Communication Toolkit - Developed a Communication Toolkit aimed at community practitioners and patients to provide basic information on antibiotic stewardship  (supported by a grant from Wellcome).
  • The Limits of Limits Case Report -  Analyzed the role of antibiotic contaminants in pharmaceutical wastewaters with a focus on India which was due to pass a law restricting pollutants discharge from manufacturing facilities. The Limit of Limits: India's Hurdles in Regulating Antimicrobial Pollution (supported by a grant from Wellcome).
  • Mentoring Students in Africa - In collaboration with Students Against Superbugs, provided mentoring activities during the AMR Writing Programme (AMR Writers and Content Creators Program : SAS-AFRICA).
  • Typhoid Report - A Vaccine is A Bridge, a report by CIDRAP-ASP's Natalie Vestin, MPH,  on the global burden of typhoid, the emergence of drug-resistant strains, and the role that typhoid conjugate vaccine campaigns could play in typhoid prevention and control.
  • Superbugs and You Podcast - Podcast mini-series (4 episodes + trailer each season) bringing together stories from patient experiences and clinicians who treat drug resistant infections. Two seasons have been completed and the third is in production, to be released late fall 2022 (supported by BD).

Partners & Collaborators

More about ASP

Our underwriters